Sharda Cropchem Ltd
SHARDACROPSharda Cropchem Ltd's earnings have outrun its stock. EPS grew +123.7% in a year against a +7.1% price move.
The sharpest disagreement: annual EPS moved +123.7% against a +7.1% price move — the market has not yet caught up with the delivery.
The price is in a downtrend (1 weeks in) while the P/E sits at the 11th percentile of its own 10-year range. Underneath, the last four quarters read improving — profit +56.4% year on year, and 157% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Sharda Cropchem Ltd trades at ₹899, in a downtrend and 1 weeks into that stage. That is −3.5% against its own 200-day average. It sits at 26% of a 52-week range of ₹772 to ₹1,256. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (16 weeks and counting).
Today the stock is in a downtrend — week 1 of stage 4, confirmed. At ₹899 it trades −3.5% versus its 200-day average and sits at 26% of its 52-week range (₹772–₹1,256).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +332% while the NIFTY 500 moved +280% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (16 weeks and counting; last ahead the week of 2026-04-30) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 11th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Sharda Cropchem Ltd trades at 12.1× P/E, near the bottom of its own range — cheaper only 11% of the time. Its long-run median P/E is 17.1×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 12.1× is near the bottom of its own range — cheaper only 11% of the time, against a long-run median of 17.1× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +123.7% against a +7.1% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +20.1%/yr price move, ~+23.8%/yr came from earnings growth and ~−3.7 pp from the multiple (compressing); over 10y, of the +9.1%/yr price move, ~+13.7%/yr came from earnings growth and ~−4.6 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Sharda Cropchem Ltd reads as mixed on its fundamental arc. Mixed — growth is normalizing off a hyper-growth base: profit growth has eased from +185.7% at its peak to +124.0% but is still expanding, ROCE lifting at 30.0%. The read is built from 12 quarters across 4 curves, on partial evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +21.9% | +9.2% | +17.1% | +15.7% |
| Profit | +124.0% | +25.8% | +24.4% | +14.6% |
| EPS | +123.7% | +25.8% | +24.3% | +14.5% |
| Share price | +7.1% | +18.2% | +20.1% | +9.1% |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
79.1/100 — rank 1 of 24 in Pesticides/Agrochemicals · 93% evidence confidence
Sharda Cropchem Ltd scores 79.1 out of 100 against the 24 companies it is compared with in Pesticides/Agrochemicals, ranking 1. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 29.4 + 21.9 + 19.2 + 8.6 = 79.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Sharda Cropchem Ltd reported ₹2,065 Cr of revenue in the Mar 26 quarter, +12.9% year on year. That is the 8th straight quarter of year-on-year growth. Over 10 years it has compounded at 15.7% a year. The last full year, FY26, came in at ₹5,268 Cr. The last four reported quarters add to ₹5,268 Cr.
Sharda Cropchem Ltd reported ₹2,065 Cr of revenue in the Mar 26 quarter, +12.9% year on year. That is the 8th straight quarter of year-on-year growth. Over 10 years it has compounded at 15.7% a year. The last full year, FY26, came in at ₹5,268 Cr. The last four reported quarters add to ₹5,268 Cr.
FY26 revenue came in at ₹5,268 Cr (+21.9% on the year), capping 10 years at 15.7% compound. The latest quarter (Mar 26) printed ₹2,065 Cr, +12.9% year on year — the 8th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +24.2% growth against the decade's 15.7% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +21.9% over the last 4 quarters against +29.1%/yr over the last 8 — rolling over; TTM profit +124.0% vs +368.7%/yr — rolling over.
→ Revenue grew — did margins hold as it scaled? Next: 24.0% this quarter (+7.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Sharda Cropchem Ltd's operating margin is 24.0% in the Mar 26 quarter, +7.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 10.0% to 23.0%. The current quarter is running above every full year in that window.
Sharda Cropchem Ltd's operating margin is 24.0% in the Mar 26 quarter, +7.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 10.0% to 23.0%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 24.0%, +7.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 10.0%–23.0%.
Why the margin moved: operating margin went +7.0 pp year on year while gross margin went +7.5 pp — the gain came mostly from the gross line: input costs and pricing.
→ Margins held — did that reach the bottom line? Next: profit +56.4% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Sharda Cropchem Ltd earned ₹319 Cr of net profit in the Mar 26 quarter, +56.4% year on year. It is the 6th consecutive quarter of growth. Full-year FY26 profit was ₹681 Cr. The 10-year compound rate is 14.6%. That is 15.4% of the quarter's revenue. The same quarter a year earlier earned ₹204 Cr.
Sharda Cropchem Ltd earned ₹319 Cr of net profit in the Mar 26 quarter, +56.4% year on year. It is the 6th consecutive quarter of growth. Full-year FY26 profit was ₹681 Cr. The 10-year compound rate is 14.6%. That is 15.4% of the quarter's revenue. The same quarter a year earlier earned ₹204 Cr.
Mar 26 profit was ₹319 Cr, +56.4% year on year — the 6th consecutive quarter of growth. On the full year, FY26 printed ₹681 Cr (+124.0%), and the 10-year compound rate is 14.6%.
Why profit moved: revenue contributed +12.9% and the margin +7.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +232.5% vs revenue +24.2%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
→ Profit rose — but did the cash follow? Next: 157% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 157% of Sharda Cropchem Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹656 Cr of operating cash against ₹681 Cr of profit. After ₹520 Cr of capital spending, ₹136 Cr was left as free cash.
FY26: operating cash of ₹656 Cr against reported profit of ₹681 Cr, leaving free cash of ₹136 Cr after ₹520 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 157% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 157%: the cash cycle stretched 11 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
→ So follow the cash to where it goes. Next: a 125-day cycle and ₹1,231 Cr of building.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Sharda Cropchem Ltd's cash conversion cycle runs 125 days in FY26, up from 114 days in FY21. Capital spending ran ₹1,231 Cr over the last 3 years. At FY26 sales of ₹5,268 Cr each day of that cycle holds about ₹14.4 Cr, so roughly ₹1,804 Cr sits inside the business at any moment.
FY26: debtors at 166 days, inventory at 121 days — roughly 4.0 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 125 days, looser than FY21's 114.
The full loop: cash goes out to suppliers and production on day 0; stock waits 121 days to sell; customers pay about 166 days after that; and suppliers themselves are paid at 162 days — netting out to the 125-day cycle.
In money terms: at FY26 sales of ₹5,268 Cr, each day of the cycle holds about ₹14.4 Cr — so the 125-day loop keeps roughly ₹1,804 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹1,231 Cr over the last 3 fiscal years against ₹867 Cr of depreciation — building somewhat ahead of wear-and-tear. Capital work-in-progress stands at ₹247 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 30% and the ROIC − WACC spread is +15.5 pp.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Sharda Cropchem Ltd earns a ROCE of 30% in FY26. That is up from a trough of 4% in FY24. Return on invested capital clears the cost of that capital by +15.5 percentage points, so growth here adds value rather than only size. The wiring behind it is 12.9% net margin on 0.92× asset turns.
FY26 ROCE is 30%, recovered from a FY24 trough of 4% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 12.9% net margin × 0.92× asset turns × 1.84× balance-sheet leverage ≈ 21.8% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 27.5% − 12.0% = a +15.5 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.00.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Sharda Cropchem Ltd carries total debt of ₹3.0 Cr against shareholder equity of ₹3,137 Cr as of Mar 26, a debt-to-equity of 0.00 — effectively unlevered. On the annual view that ratio went from 0.03 in FY22 to 0.00 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹3.0 Cr against shareholder equity of ₹3,137 Cr — a debt-to-equity of 0.00. On the annual view, debt-to-equity went from 0.03 (FY22) to 0.00 (FY26). The returns on this page are earned, not borrowed.
→ Who owns this, and are they adding or leaving? Next: Domestic institutions cut 3.7 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions cut 3.7 points of Sharda Cropchem Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 9.2% of the company. Foreign institutions moved +1.1 points over the same window, to 3.1%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: −3.7 points over 8 quarters to 9.2%; Foreign institutions: +1.1 points over 8 quarters to 3.1%; Promoters: +0.0 points over 8 quarters to 74.8%.
🚨 Why the register moved: domestic institutions drove it (−3.7 points), absorbed on the other side by foreign institutions (+1.1 points) — distribution into the market’s bid.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Sharda Cropchem Ltd: the Z-score reads 4.22. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 4.22 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 4.22.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Sharda Cropchem Ltd this page | 12.1× | ₹7,876 Cr | Mixed | |||
| UPL Ltd | 28.2× | ₹50,841 Cr | No read | |||
| P I Industries Ltd | 34.5× | ₹41,437 Cr | Deteriorating | |||
| Sumitomo Chemical India Ltd | 50.9× | ₹25,978 Cr | Mixed | |||
| Bayer CropScience Ltd | 385.0× | ₹18,954 Cr | — | — | — | — |
| Jubilant Ingrevia Ltd | 36.3× | ₹11,557 Cr | Mixed | |||
| Epigral Ltd | 15.2× | ₹5,016 Cr | Mixed | |||
| NACL Industries Ltd | 178.0× | ₹4,610 Cr | No read | |||
| Dhanuka Agritech Ltd | 15.5× | ₹4,517 Cr | Topping out | |||
| Rallis India Ltd | 26.9× | ₹4,253 Cr | Mixed | |||
| Bhagiradha Chemicals & Industries Ltd | 188.0× | ₹3,416 Cr | Improving | |||
| GSP Crop Science Ltd | 24.4× | ₹2,468 Cr | — | — | — | — |
| Bharat Rasayan Ltd | 13.1× | ₹2,096 Cr | Mixed | |||
| Insecticides India Ltd | 12.9× | ₹1,793 Cr | Mixed | |||
| India Pesticides Ltd | 14.4× | ₹1,727 Cr | Mixed | |||
| Titan Biotech Ltd | 57.5× | ₹1,719 Cr | Turning around | |||
| Astec Lifesciences Ltd | — | ₹1,469 Cr | No read | |||
| Meghmani Organics Ltd | 48.2× | ₹1,385 Cr | No read | |||
| Punjab Chemicals & Crop Protection Ltd | 21.0× | ₹1,375 Cr | Mixed | |||
| Excel Industries Ltd | 15.5× | ₹1,172 Cr | Mixed | |||
| Titan Biotech Ltd | 42.0× | ₹1,141 Cr | Turning around | |||
| Dharmaj Crop Guard Ltd | 16.1× | ₹882 Cr | No read | |||
| Advance Agrolife Ltd | 20.0× | ₹706 Cr | No read | |||
| Heranba Industries Ltd | — | ₹700 Cr | No read | |||
| Best Agrolife Ltd | 60.6× | ₹538 Cr | No read |
Frequently asked questions
What is Sharda Cropchem Ltd's share price today?
Sharda Cropchem Ltd trades at ₹899, +7.1% over the past year. The company is valued at ₹7,876 Cr. The stock sits at 26% of its 52-week range of ₹772–₹1,256, −3.5% versus its 200-day average. On the tape, the price is in a downtrend, 1 weeks in. — as of 24 July 2026.
What were Sharda Cropchem Ltd's latest quarterly results?
Sharda Cropchem Ltd reported revenue of ₹2,065 Cr and net profit of ₹319 Cr for the Mar 26 quarter. Revenue rose 12.9% and profit rose 56.4% year on year. Earnings per share were ₹35.32. The operating margin was 24.0%, 7.0 pp higher than a year earlier. — as of 24 July 2026.
What is Sharda Cropchem Ltd's revenue?
Sharda Cropchem Ltd reported revenue of ₹2,065 Cr in the Mar 26 quarter, +12.9% year on year. For the full FY26 fiscal year, revenue was ₹5,268 Cr (+21.9%). Over the last 10 years revenue compounded at 15.7% a year. — as of 24 July 2026.
What is Sharda Cropchem Ltd's profit?
Sharda Cropchem Ltd earned ₹319 Cr of net profit in the Mar 26 quarter, +56.4% year on year — the 6th straight quarter of growth. Full-year FY26 profit was ₹681 Cr. The operating margin ran 24.0% in the latest quarter. — as of 24 July 2026.
What is Sharda Cropchem Ltd's market cap?
Sharda Cropchem Ltd's market capitalisation is ₹7,876 Cr at a share price of ₹899. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Sharda Cropchem Ltd's P/E ratio?
Sharda Cropchem Ltd trades at a P/E of 12.1×, at the 11th percentile of its own 10-year range, against a long-run median of 17.1×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Sharda Cropchem Ltd pay a dividend?
Yes — Sharda Cropchem Ltd's dividend payout was 20% of profit in FY26, and it recorded a payout in each of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is Sharda Cropchem Ltd overvalued?
On its own history, Sharda Cropchem Ltd looks cheap against its own history: its P/E of 12.1× has been cheaper only 11% of the time in 10 years (long-run median 17.1×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 24 July 2026.
Is Sharda Cropchem Ltd growing?
Yes — Sharda Cropchem Ltd is growing: latest-quarter revenue +12.9% year on year, profit +56.4%, and the margin +7.0 pp at 24.0%. The 10-year compound rates are 15.7% (revenue) and 14.6% (profit). The earnings engine currently reads: improving — as of 24 July 2026.
How is Sharda Cropchem Ltd performing?
Sharda Cropchem Ltd is in a downtrend, 1 weeks in. Its latest quarter's revenue rose 12.9% and profit rose 56.4% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 16 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is Sharda Cropchem Ltd in?
Mixed — growth is normalizing off a hyper-growth base: profit growth has eased from +185.7% at its peak to +124.0% but is still expanding, ROCE lifting at 30.0%. The read comes from the last 12 quarters of growth (revenue growth +21.9% latest, profit growth +124.0% latest, eps growth +123.8% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is Sharda Cropchem Ltd in an uptrend?
No — the price is in a downtrend (week 1 of stage 4), trading −3.5% versus its 200-day average and at 26% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Sharda Cropchem Ltd beating the market?
Not lately — on a trailing-13-week view Sharda Cropchem Ltd is currently behind the NIFTY 500 (16 weeks and counting; last ahead the week of 2026-04-30), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +332% against the NIFTY 500's +280% — ahead of the index over the full window. — as of 24 July 2026.
Will Sharda Cropchem Ltd's share price go up?
This page publishes no price forecast for Sharda Cropchem Ltd. What it measures instead: the share price is ₹899, the price is in a downtrend 1 weeks in. Its P/E of 12.1× sits at the 11th percentile of its own 10-year range. — as of 24 July 2026.
Who owns Sharda Cropchem Ltd?
Promoters hold 74.8% of Sharda Cropchem Ltd, foreign institutions 3.1%, domestic institutions 9.2% and the public 12.9% (latest quarter). The biggest move on the register over the last two years: Domestic institutions cut 3.7 points over 8 quarters. — as of 24 July 2026.
Does Sharda Cropchem Ltd have too much debt?
No — Sharda Cropchem Ltd's debt-to-equity is 0.00, and operating profit covers the interest bill 50×. FY26 borrowings were ₹0.0 Cr against equity of ₹3,136 Cr. The returns on this page are earned, not borrowed — as of 24 July 2026.
What is Sharda Cropchem Ltd's capex?
Sharda Cropchem Ltd spent ₹1,231 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹520 Cr, with ₹247 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Sharda Cropchem Ltd's cash flow?
Sharda Cropchem Ltd generated ₹656 Cr of operating cash flow in FY26 and ₹136 Cr of free cash flow after ₹520 Cr of capital spending. Reported profit that year was ₹681 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Sharda Cropchem Ltd's profit real cash?
Yes — over the last 3 fiscal years, 157% of Sharda Cropchem Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹656 Cr against reported profit of ₹681 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 24 July 2026.
How financially safe is Sharda Cropchem Ltd?
On the balance sheet, the Z-score reads 4.22 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 24 July 2026.
Where is Sharda Cropchem Ltd in its business cycle?
Sharda Cropchem Ltd's FY26 operating margin was 20.0%, against a 13-year band of 10.0%–23.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 24.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Sharda Cropchem Ltd story?
The sharpest disagreement: annual EPS moved +123.7% against a +7.1% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Sharda Cropchem Ltd a stock worth studying right now?
This is not investment advice. The machine read: Sharda Cropchem Ltd's earnings have outrun its stock. EPS grew +123.7% in a year against a +7.1% price move. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.